UCSF Helen Diller Family Comprehensive Cancer Center

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies (2025) Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, et al. Journal article, Letter Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial (2025) Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, et al. Journal article BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2-Breast Cancer Treated with Endocrine Therapy with or Without Palbociclib: A Secondary PENELOPE-B Study Analysis (2025) Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, et al. Journal article Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping (2025) Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, et al. Journal article Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study (2023) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Journal article Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey (2023) Cardoso F, Rihani J, Harmer V, Harbeck N, Casas A, Rugo HS, Fasching P, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms (2022) Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, et al. Journal article, Review article Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: A real-world (RW) multi-country survey (2022) Cardoso F, Rihani J, Aubel D, De Courcy J, Harmer V, Harbeck N, Casas A, et al. Conference contribution Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms (2021) Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, et al. Journal article